This work identified high AR activity as a predictive biomarker of response to BAT and supported a treatment paradigm for PCa involving repeat cycling between AR inhibition and activation.48 This concept is being tested in the ongoing STEP-UP trial (NCT04363164), which involves repetitive sequencing between BAT and enzalutamide using two different sequencing schedules. This evidence concerns the gene AR and posterior cortical atrophy.